Opinion|Videos|September 6, 2024

Key Factors to Consider when Switching to Biosimilars

Dr Humphreys discusses key factors to consider when switching to biosimilars.

Video content above is prompted by the following:

  • To what extent should the pharmacy team prioritize supporting the switch from a reference product to a biosimilar, and what factors should be considered in making this decision?

Related to this article

mRNA vaccine bottles and syringes for preventing coronavirus or covid-19 - Image credit: kitsawet | stock.adobe.com
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.